182 related articles for article (PubMed ID: 35234262)
1.
Maeda M; Ochiai K; Michishita M; Morimatsu M; Sakai H; Kinoshita N; Sakaue M; Onozawa E; Azakami D; Yamamoto M; Ishioka K; Sadahira T; Watanabe M; Tanaka Y
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35234262
[TBL] [Abstract][Full Text] [Related]
2. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines.
Yeom J; Cho Y; Ahn S; Jeung S
Front Vet Sci; 2023; 10():1279535. PubMed ID: 38033642
[TBL] [Abstract][Full Text] [Related]
4. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma.
Wang G; Wu M; Durham AC; Radaelli E; Mason NJ; Xu X; Roth DB
PLoS One; 2020; 15(3):e0229728. PubMed ID: 32210430
[TBL] [Abstract][Full Text] [Related]
5. Alpelisib to treat breast cancer.
Copur MS
Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
[TBL] [Abstract][Full Text] [Related]
6. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
[TBL] [Abstract][Full Text] [Related]
7. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
8. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma.
Estabrooks T; Gurinovich A; Pietruska J; Lewis B; Harvey G; Post G; Lambert L; Miller A; Rodrigues L; White ME; Lopes C; London CA; Megquier K
Vet Comp Oncol; 2023 Dec; 21(4):623-633. PubMed ID: 37734854
[TBL] [Abstract][Full Text] [Related]
9. Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes.
Kodama A; Sakai H; Matsuura S; Murakami M; Murai A; Mori T; Maruo K; Kimura T; Masegi T; Yanai T
BMC Cancer; 2009 Oct; 9():363. PubMed ID: 19825192
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations matter for cancer in dogs.
Kim JH
Res Vet Sci; 2020 Dec; 133():39-41. PubMed ID: 32932196
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
13. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
15. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Kim KJ; Kim JW; Sung JH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Kim HK; Lee KW
Sci Rep; 2020 Jul; 10(1):12308. PubMed ID: 32704014
[TBL] [Abstract][Full Text] [Related]
16. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
18. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells.
Krajnak S; Trier JP; Heinzmann PF; Anic K; Heimes AS; Loewe A; Schmidt M; Battista MJ; Hasenburg A; Brenner W
EXCLI J; 2023; 22():114-130. PubMed ID: 36998707
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
